)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Sensei Biotherapeutics
Sensei Biotherapeutics (SNSE) investor relations material
Sensei Biotherapeutics M&A announcement summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.M&A announcement summary18 Feb, 2026
Deal rationale and strategic fit
Acquisition combines complementary oncology pipelines, leveraging Faeth's expertise in multi-node pathway inhibition and computational biology to advance cancer therapeutics.
PIKTOR, a multi-node PI3K/AKT/mTOR inhibitor, becomes the lead asset, targeting high unmet needs in endometrial, breast, ovarian, and lung cancers.
The combined company aims to accelerate clinical milestones and future growth in oncology, with leadership continuity and integration of key Faeth executives.
PIKTOR is designed to overcome efficacy-tolerability tradeoffs seen with single-node inhibitors.
Financial terms and conditions
Acquisition structured as a stock-for-stock merger, exchanging all Faeth equity for common and Series B non-voting convertible preferred stock.
Concurrent $200 million private placement with leading healthcare investors, shares priced at $13,850 per Series B share ($13.85 per common share equivalent), closing expected February 20, 2026.
Post-transaction, prior equityholders own 4.9%, Faeth holders 40.8%, and private placement investors 54.3% of the combined company.
Total capitalization (as converted) is 26,304,468 shares, with a market cap of $364.3 million at deal price.
Synergies and expected cost savings
Combined expertise in functional genomics, computational biology, and cancer metabolism expected to accelerate development of novel therapies and support multiple clinical milestones.
Proceeds from financing fund key clinical trials, including Phase 2 topline data in endometrial cancer and initiation of Phase 1b in breast cancer by year-end 2026.
Combined R&D and CMC infrastructure positioned for scale and registration, supporting efficient advancement of the pipeline.
Explain PIKTOR's tolerability/efficacy advantage?
How do PIKTOR's CRs inform trial design?
What is the post-deal ownership breakdown?
PIKTOR's differentiation vs. prior PI3K failures?
Justify 4.9% legacy Sensei shareholder stake.
Timeline for preclinical assets or other indications?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sensei Biotherapeutics earnings date
Q4 202513 Mar, 2026
Sensei Biotherapeutics
Next Sensei Biotherapeutics earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Sensei Biotherapeutics, Inc. is an immuno-oncology company dedicated to the discovery and development of next-generation therapeutics aimed at treating cancer patients. The company's innovative approach is centered on its TMAb™ (Tumor Microenvironment Activated biologics) platform, which develops conditionally active therapeutics. These therapeutics are designed to selectively disable checkpoints and other immunosuppressive signals in the tumor microenvironment, thereby unleashing T cells against tumors. Among its pipeline, the lead investigational candidate is SNS-101, a conditionally active antibody tailored to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint within the tumor's low pH environment, where VISTA suppresses T cell activity by binding the PSGL-1 receptor. The company is headquartered in Rockville, Maryland, with an additional office in Boston, Massachusetts, and its shares are listed on the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage